Stopping RASi treatment suppresses hyperkalaemia recurrence but ups death, MACE risk
Terminating treatment with renin-angiotensin system inhibitors (RASi) after hyperkalaemia may lower the likelihood of recurrence but aggravate the risks of death and cardiovascular events, a new study has found.
Stopping RASi treatment suppresses hyperkalaemia recurrence but ups death, MACE risk
16 Oct 2021
